This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for October 17th
by Zacks Equity Research
BAYYR, EDAP and FWRD have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2023.
SentinelOne (S) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Sentinel One's (S) fourth-quarter fiscal 2023 results are likely to reflect the benefits of strategic integrations and expanding clientele.
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement at the Animal Health segment.
EDAP TMS S.A. (EDAP) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
EDAP TMS S.A. (EDAP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks.com featured highlights include Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares
by Zacks Equity Research
Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares are part of the Zacks Screen of the Week article.
Best Momentum Stocks to Buy for November 21st
by Zacks Equity Research
ACR, EDAP and H made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 21, 2022.
New Strong Buy Stocks for November 21st
by Zacks Equity Research
AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.
5 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, EDAP, BBSI, OSBC and MNSB.
Is EDAP TMS (EDAP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how EDAP TMS S.A. (EDAP) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.
Why Earnings Season Could Be Great for EDAP TMS (EDAP)
by Zacks Equity Research
EDAP TMS (EDAP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's Why Momentum in EDAP TMS S.A. (EDAP) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, EDAP TMS S.A. (EDAP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business and informatics franchise.
Is Centene (CNC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Centene (CNC) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
Here's What Could Help EDAP TMS S.A. (EDAP) Maintain Its Recent Price Strength
by Zacks Equity Research
EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Bellus Health (BLU) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
EDAP TMS S.A. (EDAP) Moves 7.3% Higher: Will This Strength Last?
by Zacks Equity Research
EDAP TMS S.A. (EDAP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Is EDAP TMS (EDAP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how EDAP TMS S.A. (EDAP) and Indivior PLC (INVVY) have performed compared to their sector so far this year.
Here's Why Momentum in EDAP TMS S.A. (EDAP) Should Keep going
by Zacks Equity Research
EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here's Why "Trend" Investors Would Love Betting on EDAP TMS S.A. (EDAP)
by Zacks Equity Research
EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Has Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
Strength Seen in EDAP TMS S.A. (EDAP): Can Its 13.4% Jump Turn into More Strength?
by Zacks Equity Research
EDAP TMS S.A. (EDAP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Has EDAP TMS (EDAP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how EDAP TMS S.A. (EDAP) and Fstar Therapeutics, Inc. (FSTX) have performed compared to their sector so far this year.
EDAP TMS S.A. (EDAP) Stock Jumps 18.8%: Will It Continue to Soar?
by Zacks Equity Research
EDAP TMS S.A. (EDAP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.